Tactile Systems Technology Inc (TCMD) reports a robust 17% revenue increase and raises full-year guidance, despite challenges ...

Q3 2025 Management View CEO Sheri Dodd opened by highlighting "progress in both strategy and operational execution, demonstrated by meaningful advances in business transformation, product innovation ...

Tactile Systems Technology develops and sells medical devices for patients with lymphedema, a condition causing swelling due to lymphatic system issues, and for those needing help with airway ...

Tactile Systems Technology, Inc. (NASDAQ:TCMD) Q3 2024 Earnings Call Transcript November 4, 2024 Tactile Systems Technology, Inc. beats earnings expectations. Reported EPS is $0.2125, expectations ...

Tactile Systems produces medical devices for lymphedema and chronic venous insufficiency, with Flexitouch Plus being the flagship product and key revenue driver. The company's products are covered by ...

This archived news story is available only for your personal, non-commercial use. Information in the story may be outdated or superseded by additional information. Reading or replaying the story in ...

The Lymphedema Treatment Act went into effect on Jan. 1, making prescribed lymphedema compression garments approved by Medicare Part B. Medicare will now cover doctor-prescribed compression supplies ...